Innovent and GenFleet reach deal for KRAS inhibitor; TCR2 receives FDA’s ODD on gavo-cel

Amgen became the first company in May to crack an undruggable target and earn approval for a KRAS inhibitor. Now, Innovent is looking to follow in its footsteps.

Chinese pharma companies Innovent and GenFleet have entered into an exclusive licensing agreement for developing and commercializing GenFleet’s...

Click to view original post